A Phase 3 interventional study of ombitasvir/paritaprevir/ritonavir and dasabuvir in Chronic Hepatitis C, Decompensated Cirrhosis and Hepatitis C Virus, sponsored by AbbVie. Completed. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2017-07-11.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing Ombitasvir/Paritaprevir/Ritonavir in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. Ombitasvir/Paritaprevir/Ritonavir · Hepatitis C, Chronic.
Among the 10 studies testing Ombitasvir/Paritaprevir/Ritonavir in Hepatitis C, Chronic, this one is the 6th largest by enrollment, is one of 6 that started in 2014, is one of 8 in phase 3, and was the 3rd registered.
950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.
Browse Hepatitis C, Chronic studies →None of the 10 studies testing Ombitasvir/Paritaprevir/Ritonavir in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 8
First in 2014; this study’s year is marked. 6 started in 2014.
This study's enrollment of 36 is below the median of 90 across 696 interventional studies indexed under Hepatitis C, Chronic.
Median enrollment 48 across the 10 interventional studies. Of the 9 that completed or were terminated, 8 (89%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 10 have an industry lead sponsor. The 2 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
83 studies in Hepatitis C, Chronic by AbbVie: none open now, none under way, none of them phase 3. Of 82 finished, 74 (90%) have results posted.
Among the 83 studies in Hepatitis C, Chronic by AbbVie, this one is the 47th largest by enrollment of the 58 interventional ones that give a count, is one of 11 that started in 2014, is one of 40 in phase 3, and was the 22nd registered.
AbbVie’s Hepatitis C, Chronic studies by the year they started, since 2009.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing Ombitasvir/Paritaprevir/Ritonavir in Hepatitis C, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 83 in Hepatitis C, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objectives of this study are to assess the safety and the SVR12 rate of ombitasvir/paritaprevir/ritonavir and dasabuvir with RBV in GT1-infected participants with decompensated cirrhosis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ombitasvir/paritaprevir/ritonavir 25/150/100 mg once daily (QD) + dasabuvir 250 mg twice daily (BID) + ribavirin (RBV) for 12 weeks in hepatitis C virus (HCV) genotype (GT) 1b-infected participants
Drug: ombitasvir/paritaprevir/ritonavir · Drug: dasabuvir · Drug: ribavirin
ombitasvir/paritaprevir/ritonavir 25/150/100 mg QD + dasabuvir 250 mg BID + RBV for 24 weeks in HCV GT1non-b (including GT1a)-infected participants
Drug: ombitasvir/paritaprevir/ritonavir · Drug: dasabuvir · Drug: ribavirin
ombitasvir/paritaprevir/ritonavir 25/150/100 mg QD + RBV for 24 weeks in HCV GT4-infected participants
Drug: ombitasvir/paritaprevir/ritonavir · Drug: ribavirin
Drug page: Ombitasvir/Paritaprevir/Ritonavir
tablet; paritaprevir co-formulated with ritonavir and ombitasvir
Also known as: ABT-267 also known as ombitasvir, ABT-450 also known as paritaprevir, ritonavir also known as norvir
tablet
Also known as: ABT-333
tablet
Percentages of Participants With Sustained Virologic Response 12 Weeks Post-Treatment (SVR12) in Group 1 and in Group 2
SVR12, defined as HCV RNA \< lower limit of quantification (LLOQ) in the SVR12 window (12 weeks after the last actual dose of study drug) without any confirmed quantifiable (≥ LLOQ) post-treatment value before or during that SVR window. Flanking imputation: for participants with missing HCV RNA at a visit who have an undetectable HCV RNA or unquantifiable HCV RNA at the preceding visit and the succeeding visit, the missing value was imputed as undetectable or unquantifiable. For SVR analyses, if there was no value in the window after the flanking imputation but there was an HCV RNA value after the window, then it was imputed into the SVR window. After above imputations were applied, if there was still no value in the window but there was an HCV RNA value from a local laboratory present, then it was imputed into the SVR window. Otherwise, participants with missing data were counted as failures. The 95% confidence interval was calculated using the Wilson score method.
Time frame: 12 weeks after the last actual dose of study drug
Percentage of Participants With SVR12 in Group 3
SVR12, defined as HCV RNA \< LLOQ in the SVR12 window (12 weeks after the last actual dose of study drug) without any confirmed quantifiable (≥ LLOQ) post-treatment value before or during that SVR window. Flanking imputation: for participants with missing HCV RNA at a visit, who have an undetectable HCV RNA or unquantifiable HCV RNA at the preceding visit and the succeeding visit, the missing value was imputed as undetectable or unquantifiable. For SVR analyses, if there was no value in the window after the flanking imputation but there was an HCV RNA value after the window, then it was imputed into the SVR window. After above imputations were applied, if there was still no value in the window but there was an HCV RNA value from a local laboratory present, then it was imputed into the SVR window. Otherwise, participants with missing data were counted as failures.
Time frame: 12 weeks after the last actual dose of study drug
Percentage of Participants With SVR12 Non-Response Due to Experiencing On-Treatment Virologic Failure
On-treatment virologic failure was defined as: confirmed HCV RNA ≥ LLOQ after HCV RNA \< LLOQ during treatment; confirmed increase from nadir in HCV RNA (two consecutive HCV RNA measurements \> 1 log˅10 IU/mL above nadir) at any time point during treatment; or HCV RNA ≥ LLOQ persistently during treatment with at least 6 weeks (≥ 36 days) of treatment. The 95% confidence interval was calculated using Wilson score method. SVR12 was defined as HCV RNA \< LLOQ in the SVR12 window (12 weeks after the last actual dose of study drug) without any confirmed quantifiable (≥ LLOQ) post-treatment value before or during that SVR window.
Time frame: Up to 24 weeks during treatment
Percentage of Participants With SVR12 Non-Response Due to Experiencing Relapse˅12
Relapse˅12 was defined as confirmed HCV RNA ≥ LLOQ between end of treatment and 12 weeks after last actual dose of active study drug (up to and including the SVR12 window) for a participant with HCV RNA \< LLOQ at final treatment visit who completes treatment and has post-treatment HCV RNA data. Completion of treatment was defined as a study drug duration ≥ 77 days for participants assigned to 12 weeks of treatment or ≥ 154 days for participants assigned to 24 weeks of treatment. SVR12 was defined as HCV RNA \< LLOQ in the SVR12 window (12 weeks after the last actual dose of study drug) without any confirmed quantifiable (≥ LLOQ) post-treatment value before or during that SVR window. The 95% confidence interval was calculated using the Wilson score method.
Time frame: Up to 12 weeks after the last actual dose of study drug
Percentage of Participants With Improvement From Baseline to Post-Treatment Week 12 in Hepatic Function Tests
Improvement was defined as: * increase of more than 0.2 g/L from baseline to post-treatment Week 12 in albumin * decrease of more than 0.3 µmol/L from baseline to post-treatment Week 12 in bilirubin * decrease of more than 5 ng/mL from baseline to post-treatment Week 12 in alpha-fetoprotein * increase of more than 15\*10\^9/L from baseline to post-treatment Week 12 in platelet count * decrease of more than 0.2 from baseline to post-treatment Week 12 in international normalized ratio.
Time frame: Up to post-treatment Week 12
Percentage of Participants With Improvement From Baseline to Post-Treatment Week 12 in FibroTest
The FibroTest score is used to assess liver fibrosis. Scores range from 0.00 to 1.00, with higher scores indicating a greater degree of fibrosis. Improvement was defined as a decrease of more than 0.2 from baseline to post-treatment Week 12.
Time frame: Up to post-treatment Week 12
Percentage of Participants With Improvement From Baseline to Post-Treatment Week 12 in Chld-Pugh Score
The The Child-Pugh score uses five clinical measures of liver disease (3 laboratory parameters and 2 clinical assessments) to measure severity of cirrhosis. Scores range from 5 to 15, with higher scores indicating more severity. Improvement was defined as a decrease of 1 or more from baseline to post-treatment Week 12.
Time frame: Up to post-treatment Week 12
Percentage of Participants With Improvement From Baseline to Post-Treatment Week 12 in Model for End-Stage Liver Disease (MELD) Score
MELD is a scoring system for assessing the severity of chronic liver disease. Scores range from 6 to 40, with higher scores indicating more severity. Improvement was defined as a decrease of 1 or more from baseline to post-treatment Week 12.
Time frame: Up to post-treatment Week 12
| Milestone | Group 1: GT1B | Group 2: GT1 Non-B | Group 3: GT4 |
|---|---|---|---|
| Started | 9 | 24 | 3 |
| Completed | 9 | 22 | 2 |
| Not completed | 0 | 2 | 1 |
| Withdrew: Adverse event | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 |
SVR12, defined as HCV RNA \< lower limit of quantification (LLOQ) in the SVR12 window (12 weeks after the last actual dose of study drug) without any confirmed quantifiable (≥ LLOQ) post-treatment value before or during that SVR window. Flanking imputation: for participants with missing HCV RNA at a visit who have an undetectable HCV RNA or unquantifiable HCV RNA at the preceding visit and the succeeding visit, the missing value was imputed as undetectable or unquantifiable. For SVR analyses, if there was no value in the window after the flanking imputation but there was an HCV RNA value after the window, then it was imputed into the SVR window. After above imputations were applied, if there was still no value in the window but there was an HCV RNA value from a local laboratory present, then it was imputed into the SVR window. Otherwise, participants with missing data were counted as failures. The 95% confidence interval was calculated using the Wilson score method.
| percentage of participants | Group 1: GT1B | Group 2: GT1 Non-B |
|---|---|---|
| Percentages of Participants With Sustained Virologic Response 12 Weeks Post-Treatment (SVR12) in Group 1 and in Group 2 | 100 (70.1 to 100.0) | 95.8 (79.8 to 99.3) |
SVR12, defined as HCV RNA \< LLOQ in the SVR12 window (12 weeks after the last actual dose of study drug) without any confirmed quantifiable (≥ LLOQ) post-treatment value before or during that SVR window. Flanking imputation: for participants with missing HCV RNA at a visit, who have an undetectable HCV RNA or unquantifiable HCV RNA at the preceding visit and the succeeding visit, the missing value was imputed as undetectable or unquantifiable. For SVR analyses, if there was no value in the window after the flanking imputation but there was an HCV RNA value after the window, then it was imputed into the SVR window. After above imputations were applied, if there was still no value in the window but there was an HCV RNA value from a local laboratory present, then it was imputed into the SVR window. Otherwise, participants with missing data were counted as failures.
| percentage of participants | Group 3: GT4 |
|---|---|
| Percentage of Participants With SVR12 in Group 3 | 66.7 |
On-treatment virologic failure was defined as: confirmed HCV RNA ≥ LLOQ after HCV RNA \< LLOQ during treatment; confirmed increase from nadir in HCV RNA (two consecutive HCV RNA measurements \> 1 log˅10 IU/mL above nadir) at any time point during treatment; or HCV RNA ≥ LLOQ persistently during treatment with at least 6 weeks (≥ 36 days) of treatment. The 95% confidence interval was calculated using Wilson score method. SVR12 was defined as HCV RNA \< LLOQ in the SVR12 window (12 weeks after the last actual dose of study drug) without any confirmed quantifiable (≥ LLOQ) post-treatment value before or during that SVR window.
| percentage of participants | Group 1: GT1B | Group 2: GT1 Non-B | Group 3: GT4 |
|---|---|---|---|
| Percentage of Participants With SVR12 Non-Response Due to Experiencing On-Treatment Virologic Failure | 0 (0.0 to 29.9) | 0 (0.0 to 13.8) | 0 (NA to NA) |
Relapse˅12 was defined as confirmed HCV RNA ≥ LLOQ between end of treatment and 12 weeks after last actual dose of active study drug (up to and including the SVR12 window) for a participant with HCV RNA \< LLOQ at final treatment visit who completes treatment and has post-treatment HCV RNA data. Completion of treatment was defined as a study drug duration ≥ 77 days for participants assigned to 12 weeks of treatment or ≥ 154 days for participants assigned to 24 weeks of treatment. SVR12 was defined as HCV RNA \< LLOQ in the SVR12 window (12 weeks after the last actual dose of study drug) without any confirmed quantifiable (≥ LLOQ) post-treatment value before or during that SVR window. The 95% confidence interval was calculated using the Wilson score method.
| percentage of participants | Group 1: GT1B | Group 2: GT1 Non-B | Group 3: GT4 |
|---|---|---|---|
| Percentage of Participants With SVR12 Non-Response Due to Experiencing Relapse˅12 | 0 (0.0 to 35.4) | 0 (0.0 to 16.8) | 0 (NA to NA) |
Improvement was defined as: * increase of more than 0.2 g/L from baseline to post-treatment Week 12 in albumin * decrease of more than 0.3 µmol/L from baseline to post-treatment Week 12 in bilirubin * decrease of more than 5 ng/mL from baseline to post-treatment Week 12 in alpha-fetoprotein * increase of more than 15\*10\^9/L from baseline to post-treatment Week 12 in platelet count * decrease of more than 0.2 from baseline to post-treatment Week 12 in international normalized ratio.
| percentage of participants | Group 1: GT1B | Group 2: GT1 Non-B | Group 3: GT4 |
|---|---|---|---|
| Albumin | 77.8 | 77.3 | 50.0 |
| Bilirubin | 66.7 | 72.7 | 100 |
| Alpha-fetoprotein | 33.3 | — | — |
| Platelet count | 22.2 | 14.3 | 0 |
| International normalized ratio | 0 | 0 | 0 |
The FibroTest score is used to assess liver fibrosis. Scores range from 0.00 to 1.00, with higher scores indicating a greater degree of fibrosis. Improvement was defined as a decrease of more than 0.2 from baseline to post-treatment Week 12.
| percentage of participants | Group 1: GT1B | Group 2: GT1 Non-B | Group 3: GT4 |
|---|---|---|---|
| Percentage of Participants With Improvement From Baseline to Post-Treatment Week 12 in FibroTest | 0 | 9.1 | 50.0 |
The The Child-Pugh score uses five clinical measures of liver disease (3 laboratory parameters and 2 clinical assessments) to measure severity of cirrhosis. Scores range from 5 to 15, with higher scores indicating more severity. Improvement was defined as a decrease of 1 or more from baseline to post-treatment Week 12.
| percentage of participants | Group 1: GT1B | Group 2: GT1 Non-B | Group 3: GT4 |
|---|---|---|---|
| Percentage of Participants With Improvement From Baseline to Post-Treatment Week 12 in Chld-Pugh Score | 66.7 | 54.5 | 50.0 |
MELD is a scoring system for assessing the severity of chronic liver disease. Scores range from 6 to 40, with higher scores indicating more severity. Improvement was defined as a decrease of 1 or more from baseline to post-treatment Week 12.
| percentage of participants | Group 1: GT1B | Group 2: GT1 Non-B | Group 3: GT4 |
|---|---|---|---|
| Percentage of Participants With Improvement From Baseline to Post-Treatment Week 12 in Model for End-Stage Liver Disease (MELD) Score | 87.5 | 61.9 | 100 |
Collected over Protocol-related treatment-emergent adverse events and treatment-emergent serious adverse events were collected from the first dose of study drug until post treatment Day 30; treatment was up to Week 12 for Group 1, and up to Week 24 for Groups 2 and 3.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1: GT1B | — | 1/9 (11.1%) | 8/9 (88.9%) |
| Group 2: GT1 Non-B | — | 10/24 (41.7%) | 24/24 (100%) |
| Group 3: GT4 | — | 1/3 (33.3%) | 3/3 (100%) |
| Event | Group 1: GT1B | Group 2: GT1 Non-B | Group 3: GT4 |
|---|---|---|---|
| ASCITESGastrointestinal disorders | 1/9 | 1/24 | 1/3 |
| DIARRHOEAGastrointestinal disorders | 0/9 | 0/24 | 1/3 |
| GENERAL PHYSICAL HEALTH DETERIORATIONGeneral disorders | 0/9 | 0/24 | 1/3 |
| HEPATIC FAILUREHepatobiliary disorders | 0/9 | 0/24 | 1/3 |
| HYPERBILIRUBINAEMIAHepatobiliary disorders | 1/9 | 1/24 | 1/3 |
| ACCIDENTAL OVERDOSEInjury, poisoning and procedural complications | 0/9 | 0/24 | 1/3 |
| DEHYDRATIONMetabolism and nutrition disorders | 0/9 | 1/24 | 1/3 |
| ELECTROLYTE IMBALANCEMetabolism and nutrition disorders | 0/9 | 0/24 | 1/3 |
| HYPONATRAEMIAMetabolism and nutrition disorders | 0/9 | 1/24 | 1/3 |
| HEPATIC ENCEPHALOPATHYNervous system disorders | 0/9 | 2/24 | 1/3 |
| Event | Group 1: GT1B | Group 2: GT1 Non-B | Group 3: GT4 |
|---|---|---|---|
| ABDOMINAL PAINGastrointestinal disorders | 0/9 | 3/24 | 3/3 |
| NAUSEAGastrointestinal disorders | 2/9 | 13/24 | 2/3 |
| FATIGUEGeneral disorders | 3/9 | 11/24 | 2/3 |
| DIZZINESSNervous system disorders | 1/9 | 7/24 | 2/3 |
| INSOMNIAPsychiatric disorders | 0/9 | 6/24 | 2/3 |
| PANIC ATTACKPsychiatric disorders | 0/9 | 0/24 | 2/3 |
| DIARRHOEAGastrointestinal disorders | 3/9 | 10/24 | 1/3 |
| LEUKOCYTOSISBlood and lymphatic system disorders | 0/9 | 0/24 | 1/3 |
| ABDOMINAL PAIN UPPERGastrointestinal disorders | 0/9 | 3/24 | 1/3 |
| ASCITESGastrointestinal disorders | 0/9 | 8/24 | 1/3 |
| Age, Customized(Participants) | Group 1: GT1B | Group 2: GT1 Non-B | Group 3: GT4 | Total |
|---|---|---|---|---|
| < 65 years | 7 | 20 | 2 | 29 |
| >= 65 years | 2 | 4 | 1 | 7 |
| Sex: Female, Male(Participants) | Group 1: GT1B | Group 2: GT1 Non-B | Group 3: GT4 | Total |
|---|---|---|---|---|
| Female | 2 | 7 | 1 | 10 |
| Male | 7 | 17 | 2 | 26 |
No study locations are listed for this record.
Ran from Nov 2014 to primary completion in Jun 2016, 18 months.
Results were first posted in Jul 2017, 1 year after primary completion.
Of 41 industry-sponsored phase 3 interventional studies under Hepatitis C, Chronic, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 18 months is above that.
Counting every sponsor, half of 50 studies reached it within 15 months; a quarter within 10 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ombitasvir/Paritaprevir/Ritonavir · Ribavirin